CAS NO: | 171500-79-1 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Dalbavancin (MDL-63397) is a semisynthetic lipoglycopeptideantibioticwith potent bactericidal activity againstGram-positive bacteria. Dalbavancin inhibitsStaphylococcus aureusandBacillus anthraciswith MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively[1][2]. | ||||||||
IC50& Target |
| ||||||||
体外研究 (In Vitro) | Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens includingS. aureus(MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA andβ-hemolytic streptococci, organisms against which it has shown greater potency than existing glycopeptide therapeutic agents[1][2]. | ||||||||
体内研究 (In Vivo) | Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens[1].
| ||||||||
Clinical Trial | |||||||||
分子量 | 1816.69 | ||||||||
Formula | C88H100Cl2N10O28 | ||||||||
CAS 号 | 171500-79-1 | ||||||||
中文名称 | 达巴万星;道古霉素 | ||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |